Impax Parkinson’s Therapy Suffers Manufacturing Setback During FDA Review
This article was originally published in The Pink Sheet Daily
FDA dealt Impax Pharmaceuticals a “complete response” for its extended-release carbidopa/levodopa therapy for spasms suffered by Parkinson’s disease patients, rejecting the drug combo based on unresolved manufacturing issues at the firm’s Hayward, Calif., plant, though Impax has said it will manufacture the product, now called Rytary, exclusively at its Taiwan facility.
You may also be interested in...
Since Impax Laboratories’ CEO Wilkinson took the helm in April, the company has completed several significant deals and most recently restructured R&D to deliver savings, but a successful turnaround will require resolving outstanding manufacturing issues.
By acquiring three interrelated, privately held companies, Impax adds several branded and generic products, a substantial generic pipeline and an FDA-licensed manufacturing site in New Jersey.
In recent warning letters, FDA continued to hammer manufacturers for inadequate investigation of out-of-specification results and lax oversight of manufacturing operations by quality control units.